TOP TEN perturbations for 1552801_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552801_at
Selected probe(set): 229499_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552801_at (229499_at) across 6672 perturbations tested by GENEVESTIGATOR:

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)

Relative Expression (log2-ratio):5.7859964
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (confluent)
Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):5.6822233
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.

lung adenocarcinoma study 5 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):3.567809
Number of Samples:3 / 20
Experimental lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

lung adenocarcinoma study 5 (K-RAS mut) / lung adenocarcinoma study 5 (EML4-ALK)

Relative Expression (log2-ratio):-3.0879536
Number of Samples:14 / 3
Experimental lung adenocarcinoma study 5 (K-RAS mut)
Primary tumor sample from patients with stage I adenocarcinoma carrying a K-RAS mutation.
Control lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.

lung adenocarcinoma study 5 (EML4-ALK) / lung adenocarcinoma study 5 (EGFR/K-RAS/ALK -)

Relative Expression (log2-ratio):3.082697
Number of Samples:3 / 48
Experimental lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control lung adenocarcinoma study 5 (EGFR/K-RAS/ALK -)
Primary tumor sample from patients with triple-negative stage I adenocarcinoma of the lung. The patients were not carrying any mutation in the EGFR, K- RAS or ALK gene.

lung adenocarcinoma study 6 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):2.74341
Number of Samples:8 / 20
Experimental lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

lung adenocarcinoma study 6 (K-RAS mut) / lung adenocarcinoma study 6 (EML4-ALK)

Relative Expression (log2-ratio):-2.7319603
Number of Samples:6 / 8
Experimental lung adenocarcinoma study 6 (K-RAS mut)
Primary tumor sample from patients with stage II adenocarcinoma carrying a K-RAS mutation.
Control lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.

lung adenocarcinoma study 5 (EGFR mut) / lung adenocarcinoma study 5 (EML4-ALK)

Relative Expression (log2-ratio):-2.6103363
Number of Samples:103 / 3
Experimental lung adenocarcinoma study 5 (EGFR mut)
Primary tumor sample from patients with stage I adenocarcinoma carrying an EGFR mutation.
Control lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.

smoking study 65 (24h) / normal sham-exposed bronchial organotypic tissue

Relative Expression (log2-ratio):-2.4086943
Number of Samples:3 / 3
Experimental smoking study 65 (24h)
Human bronchial organotypic tissue culture exposed at the air-liquid interface to 16.7% (vol/vol) mainstream cigarette smoke of 4 cigarettes (3R4F, 6-7 minutes each) followed by fresh culture medium incubation for 24 hours. Cigarettes were smoked on a 30-port carousel smoking machine according to health Canada regimen with 1 hour rest between each cigarette. Organotypic culture consisted in a co-culture of primary bronchial respiratory epithelial cells derived from a healthy nonsmoking 67-year-old Caucasian female and primary airway fibroblasts derived from a healthy nonsmoking 61-year-old Caucasian male.
Control normal sham-exposed bronchial organotypic tissue
Human bronchial organotypic tissue culture exposed at the air-liquid interface to 60% humidified air (4 exposure with 1 hour rest between each treatment) followed by fresh culture medium incubation for 24 hours. Organotypic culture consisted in a co-culture of primary bronchial respiratory epithelial cells derived from a healthy nonsmoking 67-year-old Caucasian female and primary airway fibroblasts derived from a healthy nonsmoking 61-year-old Caucasian male.

diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)

Relative Expression (log2-ratio):2.3660536
Number of Samples:34 / 19
Experimental diabetes type 2 study 27 (LCM)
Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year.
Control diabetes type 2 study 27 (enzymatic)
Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies.